Company Overview
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain injury. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Lakewood Ranch, Florida.
Why Investors Should Care
Trades at a P/E of 0.5, below the sector median of 24.8.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -54.58% |
| 6 Months: | -45.59% |
| 3 Months: | -12.95% |
| 1 Month: | -5.04% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)48.40 · Neutral
P/E of 0.53 is below the sector median of 24.83 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 63.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | OGEN Oragenics, Inc. PHARMA | 0.52 | 0.53 | $2.35M | 0.00% | -113.05% | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 15.08K | 30.39K | 86.05K | 17.02K | 13.16K | 7.47K | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0 | - | 172.30K | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.03M | 1.71M | 3.12M | 2.50M | 2.26M |
| Operating Income | -1.87M | - | -2.07M | -1.73M | -2.03M | - | -1.99M | -1.40M | -1.92M | - | -2.12M | -2.28M | -2.76M | - | -3.39M | -4.90M | -3.92M | - | -5.23M | -12.35M | -4.51M | - | -5.24M | -3.84M | -4.39M | -4.61M | -3.60M | -3.91M | -2.90M | -3.11M | -2.09M | -2.46M | -2.31M | -2.44M | - | -2.03M | -1.71M | -3.12M | -2.50M | -2.26M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.02M | -1.70M | -3.06M | -2.42M | -2.22M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 199.13K | 572.31K | 7.04K | 7.45K | 3.73K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.22M | -2.27M | -3.07M | -2.42M | -2.22M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | - | - | - | -22.62K |
| Net Income | -1.86M | -2.22M | -2.06M | -312.62K | -1.96M | -2.67M | -1.98M | -1.22M | -2.07M | -1.46M | -2.12M | -2.28M | -2.76M | -2.76M | -3.33M | -4.81M | -3.84M | -3.60M | -5.19M | -12.34M | -4.50M | -4.41M | -5.22M | -3.82M | -4.38M | -4.59M | -3.59M | -3.87M | -2.84M | -3.05M | -2.01M | -2.45M | -2.31M | -2.46M | - | -2.22M | -2.27M | -3.07M | -2.29M | -2.20M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.85 | -1.99 | -1.41 | -1.51 | -0.85 | -0.70 | -15.27 | -11.32 | - | -3.65 | -3.10 | -1.96 | - | -0.51 |
| R&D Expense | 1.10M | - | 1.22M | 792.70K | 924.80K | - | 1.12M | 605.41K | 996.48K | - | 1.33M | 1.27M | 1.58M | - | 2.41M | 3.88M | 3.07M | - | 3.71M | 11.54M | 3.50M | - | 3.26M | 2.47M | 3.55M | 3.29M | 2.59M | 2.78M | 1.67M | 2.01M | 769.35K | 663.41K | 906.78K | 879.04K | - | 341.54K | 449.68K | 930.89K | - | 645.47K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.31M | 1.44M | 1.33M | 1.03M | 939.93K | 0 | 0 | 0 | - | - | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | 453.30K | 688.88K | 570.33K | 0 | 0 | 0 | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | 14.42M | 20.90M | 10.56M | 9.36M |
| Operating Income | -7.90M | -7.35M | -12.43M | -16.21M | -5.82M | -11.78M | -8.54M | -6.72M | -9.99M | -15.88M | -26.64M | - | -14.42M | -20.90M | -10.56M | -9.36M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | -14.23M | -20.60M | -10.54M | -9.19M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | 15.10K | 30.59K | 29.83K | 785.93K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | -14.29M | -20.66M | -10.57M | -9.98M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | -136.91K |
| Net Income | -7.81M | -7.68M | -13.09M | -16.07M | -5.79M | -11.71M | -7.01M | -6.73M | -9.91M | -15.57M | -26.43M | - | -14.29M | -20.66M | -10.57M | -9.84M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | -213.30 | -275.40 | -47.88 | -4.56 |
| R&D Expense | 2.01M | 2.45M | 7.86M | 9.36M | 3.07M | 8.73M | 4.75M | 3.54M | 5.97M | 12.12M | 22.11M | 10.59M | 10.07M | 15.49M | 4.11M | 2.39M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 1.73M | 1.27M | 10.49M | 16.83M | 11.13M | 5.78M | 4.31M | 7.21M | 22.05M | 19.75M | 18.68M | - | 14.76M | 4.97M | 1.47M | 10.07M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.29M | 3.87M | 1.47M | 10.07M |
| Cash & Equivalents | 301.59K | 132.10K | 171.74K | 9.93M | 16.28M | 10.45M | 5.08M | 4.08M | 6.17M | 20.21M | 18.27M | 17.64M | - | 11.43M | 3.48M | 864.84K | 4.40M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | 6.99K | 0 | - | 0 | 53.08K |
| Total Liabilities | - | 3.63M | 9.45M | - | - | - | - | - | - | - | - | - | - | 1.75M | 1.80M | 1.68M | 1.79M |
| Current Liabilities | - | 1.63M | 9.45M | 1.26M | 992.85K | 796.27K | 1.05M | 1.34M | 898.52K | 1.17M | 1.85M | 1.34M | - | 1.60M | 1.80M | 1.68M | 1.79M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | 624.53K | 322.51K | 328.53K | 227.35K |
| Total Equity | 2.64M | -1.90M | -8.18M | 9.23M | 15.84M | 10.34M | 4.73M | 2.97M | 6.32M | 20.88M | 17.23M | 16.84M | - | 13.01M | 3.17M | -211.88K | 8.28M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | 67.49K | 102.69K | 419.00K | 4.27M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -6.45M | -5.49M | -5.21M | - | - | -5.19M | -7.08M | -6.36M | -9.08M | -13.01M | -16.95M | - | -15.23M | -7.29M | -8.60M | -9.25M |
| Investing Cash Flow | -88.08K | - | -11.10K | - | - | -101.23K | 1.68M | - | -124.73K | -25.21K | - | -43.88K | -115.52K | -936.28K | 0 | - |
| Financing Cash Flow | 6.37M | 5.53M | 14.98M | - | - | -159.95K | 4.45M | 8.45M | 23.25M | 11.10M | 16.32M | - | -494.92K | 283.88K | 5.98M | 16.78M |
| Capital Expenditure | -88.08K | - | -11.10K | -18.81K | -110.67K | -102.51K | -27.18K | - | -124.73K | -25.21K | - | -43.88K | -127.52K | -1.00M | - | - |
| Free Cash Flow | -6.54M | - | -5.22M | - | - | -5.29M | -7.10M | - | -9.20M | -13.04M | - | - | -15.36M | -8.29M | -8.60M | -9.25M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | -15.84M | -7.94M | -2.62M | 7.53M |
| Share Buybacks | - | 3.75K | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | 34.0% | 66.7% | 60.7% | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -603.8% | -508.6% | -933.5% | -1,570.4% | -618.8% | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | -596.3% | -531.6% | -982.9% | -1,556.7% | -616.0% | - | - | - | - | - | - | - | - | - | - | - |
| ROE % | 410.9% | 93.9% | -141.8% | -101.5% | -56.0% | -247.5% | -236.5% | -106.6% | -47.5% | -90.3% | -156.9% | - | -109.8% | -652.0% | 4,987.6% | -118.9% |
| ROCE % | -7,849.0% | 89.8% | -134.7% | -102.3% | -56.3% | -249.0% | -288.0% | -106.4% | -47.9% | -88.7% | -153.7% | - | -109.6% | -659.8% | 4,983.3% | -113.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Geode Capital Management, LLC | 0.52% | 23.68K | $11.29K |
| 2 | 25 LLC | 0.51% | 23.16K | $11.04K |
| 3 | Jane Street Group, LLC | 0.28% | 12.77K | $6.09K |
| 4 | Tower Research Capital LLC (TRC) | 0.10% | 4.55K | $2.17K |
| 5 | St. Johns Investment Management Company, LLC | 0.04% | 1.92K | $917 |
| 6 | Blackrock Inc. | 0.02% | 703 | $335 |
| 7 | UBS Group AG | 0.01% | 642 | $306 |
| 8 | Harbour Investments, Inc. | - | 34 | $16 |
| 9 | Wells Fargo & Company | - | 34 | $16 |
| 10 | SBI Securities Co., Ltd. | - | 23 | $10 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for OGEN
Oragenics (NYSE: OGEN) faces NYSE listing warning as equity falls short - Stock Titan
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxNeDZIYTlNYVRPTllVVnduOV9GaDZDNmVlcUFzaW9EcmduQmgwaWhmMjFwQnhROUZTUFBISkFNQjdIMFBoU2Y2WEdIQlZEb3hsaDhWbnZIVjNZZ3VPOXE5anpTYVlZV1NRX1ctSXNMT3NvSkdFX0ZYY2VFRU9VV2xHSW4yTDBGd0JaUHkydX…
OGEN - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFBwUHBpTWdTcGtLTVplSEludHlEU0pVT2cxZFlKcE5WTjhCSTY4TXJnQW9yQ3dacERiNFFFQXJZd3pjUjFqMWc?oc=5" target="_blank">OGEN</a> <font color="#6f6f6f">Finviz</font>…
ETFs Investing in ALTEOGEN Inc. Stocks - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiYkFVX3lxTE9nWk56R2tpWnRxekFCdThRM0d0UGFFdFFVZjBtMk5qR205V0tOVzNXZ3Q4enJLejZfMGtPMGFwVTBXWTVzOEhIRlR3Q2lGeFd1YVNULXk2MlQ5X1JWRUNNOUN3?oc=5" target="_blank">ETFs Investing in ALTEOGEN Inc. Sto…
Oragenics Updates Phase IIa Trial Progress, FDA Regulatory Pathway and NYSE American Listing Status - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxQLWo0WW9QZmpNU2hEVHpUbXd0Tm1BYWdfcVZ2TXNhc20wcEhNQmxiMnRUeE1ReTM5Vm9ONGoycl90NVlVdGNYMU1KLUVsdzNvazhKWXB4TjFscVBneXIybk5KbjduYTdjeTJvMlBDVVdPMHZiUC03ZUNuX3VYNENZNlp3SndQY0kxRUdZbH…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTFA3VEF4cExfS0hXRW5BVHdCdm8ySk94c0dwN1JTM1RqN1JNUmpXRXBka1V0WFFGMnRld3VDLU9oazdLTzBxRzd6TlFrOHJJYzdK?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
Oragenics Inc. (OGEN) Holds Near Support Amid Modest Decline - Technical Analysis - vinanet.vn
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxNa2JYd3FESTVfZjZKdzVXaHJCNWJmRV9YckJRSGw0a09kRUJLS0xEVmJXVjNHbGNoazdMb0ljX19ybXAwdEZYT1FxVEpUSEVmbTIwOF9OXzZxZ0tuMXlHb0xsalJoWk9xeEx6Z3lOeVBWSTY1NGRwYzh3WXNoYi1zb0Ezazg0ZW1IajI1R0…
OGEN — Frequently Asked Questions
What is the current share price of Oragenics, Inc. (OGEN)?
As of 2026-09-19 21:16 PDT, Oragenics, Inc. (OGEN) trades at $0.52 on NYSE American. Its 52-week range is $0.49 to $1.42.
What is the market capitalisation of OGEN?
Oragenics, Inc. (OGEN) has a market capitalisation of $2.35M on NYSE American.
What is the P/E ratio of OGEN?
OGEN trades at a trailing price-to-earnings (P/E) ratio of 0.53. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.34.
Is OGEN a good stock to buy?
This page provides a data-driven analysis of Oragenics, Inc. (OGEN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.